Condition: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Sponsor: Tianjin Medical University Cancer Institute and Hospital
The efficacy and safety of combination with Disitamab Vedotin and with Tislelizumab and Capecitabine for perioperative treatment of locally advanced gastric cancer with HER2 overexpression.
This description comes directly from the study's public registry record.
Xuewei Ding, Ph.D · 18622220158 · xding@tmu.edu.cn
Han Liang, Ph.D
Always discuss trial participation with your own doctor first.
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| Xuewei Ding | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06560528